Cost of poor adherence to anti-hypertensive therapy in five European countries
Tóm tắt
The financial burden for EU health systems associated with cardiovascular disease (CV) has been estimated to be nearly €110 billion in 2006, corresponding to 10 % of total healthcare expenditure across EU or a mean €223 annual cost per capita. The main purpose of this study is to estimate the costs related to hypertension and the economic impact of increasing adherence to anti-hypertensive therapy in five European countries (Italy, Germany, France, Spain and England). A probabilistic prevalence-based decision tree model was developed to estimate the direct costs of CV related to hypertension (CV defined as: stroke, heart attack, heart failure) in five European countries. Our model considered adherence to hypertension treatment as a main driver of blood pressure (BP) control (BP < 140/90 mmHg). Relative risk of CV, based on controlled or uncontrolled BP group, was estimated from the Framingham Heart Study and national review data. Prevalence and cost data were estimated from national literature reviews. A national payer (NP) perspective for 10 years was considered. Probabilistic sensitivity analysis was performed in order to evaluate uncertainty around the results (given as 95 % confidence intervals). The model estimated a total of 8.6 million (1.4 in Italy, 3.3 in Germany, 1.2 in Spain, 1.8 in France and 0.9 in England) CV events related to hypertension over the 10-year time horizon. Increasing the adherence rate to anti-hypertensive therapy to 70 % (baseline value is different for each country) would lead to 82,235 fewer CV events (24,058 in Italy, 7,870 in Germany, 18,870 in Spain, 24,855 in France and 6,553 in England). From the NP perspective, the direct cost associated with hypertension was estimated to be €51.3 billion (8.1 in Italy, 17.1 in Germany, 12.2 in Spain, 8.8 in France and 5.0 in England). Increasing adherence to anti-hypertensive therapy to 70 % would save a total of €332 million (CI 95 %: €319–346 million) from the NPs perspective. This study is the first attempt to estimate the economic impact of non-adherence amongst patients with diagnosed hypertension in Europe, using data from five European countries (Italy, France, Germany, Spain and England).
Tài liệu tham khảo
European Innovation partnership on active and healthy aging. Action group 1. https://webgate.ec.europa.eu/eipaha/actiongroup/index/a1
WHO global health observatory data repository (2013). http://apps.who.int/gho/data/node.main.887. Accessed Feb 2013
Leal, J., Luengo-Fernández, R., Gray, A., Petersen, S., Rayner, M.: Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J. 27(13), 1610–1619 (2006). Epub 2006 Feb 22
Ong, K.L., Cheung, B.M., Man, Y.B., Lau, C.P., Lam, K.S.: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 49(1), 69–75 (2007). [PubMed:17159087]
Krousel-Wood, M.A., Muntner, P., He, J., Whelton, P.K.: Primary prevention of essential hypertension. Med. Clin. North Am. 88, 223–238 (2004). [PubMed: 14871061]
The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure.The JNC 7 report. JAMA 2003/289 2560–2572 [PubMed:12748199]
Morisky, D.E., Ang, A., Krousel-Wood, M., Ward, H.J.: Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. (Greenwich) 10(5), 348–354 (2008)
DiMatteo, M.R., Giordani, P.J., Lepper, H.S., Croghan, T.W.: Patient adherence and medical treatment outcomes: a meta-analysis. Discov. Med. 40, 794–811 (2002). [PubMed: 12218770]
Monane, M., Bohn, R.L., Gurwitz, J.H., Glynn, R.J., Levin, R., Avorn, J.: The effects of initial drug choice and comorbidity on antihypertensive therapy compliance. Results from a population-based study in the elderly. AJH 10, 697–704 (1997)
Degli Esposti, L., Saragoni, S., Benemei, S., Batacchi, P., Geppetti, P., Di Bari, M., Marchionni, N., Sturani, A., Buda, S., Degli Esposti, E.: Adherence to anti-hypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon. Outcomes Res. 3, 47–54 (2011). doi:10.2147/CEOR.S15619. (Epub 2011 Mar 7)
DiMatteo, M.R.: Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med. Care 42(3), 200–209 (2004). (Assuming normal distribution)
Girerd, X., Radauceanu, A., et al.: Evaluation de l’observance par l’interrogatoire au cours du suivi des hypertendus dans des consultations spécialisées. Arch. Mal. Coeur Vaiss. 94(8), 839–842 (2001)
Breitscheidel, L., Ehlken, B., Kostev, K., Oberdiek, A., Sandberg, A., Schmieder, R.E.: Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. J. Med. Econ. 15(1), 155–165 (2012)
Clarke, P., Gray, A., Legood, R., Briggs, A., Holman, R.: The impact of diabetes-related complications on healthcare costs: results from the United Kingdom prospective diabetes study (UKPDS 65). Diabet. Med. 20(6), 442–450 (2003)
Koçkaya, G., Wertheimer, A.: Can we reduce the cost of illness with more compliant patients? An estimation of the effect of 100% compliance with hypertension treatment. J. Pharm. Pract. 24(3), 345–350 (2011). doi:10.1177/0897190010389336. (Epub 2010 Feb 20)
Cramer, J.A., Roy, A., Burrell, A., Fairchild, C.J., Fuldeore, M.J., Ollendorf, D.A., Wong, P.K.: Medication compliance and persistence: terminology and definitions. Value Health 11(1), 44–47 (2008). doi:10.1111/j.1524-4733.2007.00213.x
D’Agostino Sr, R.B., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M., Kannel, W.B.: General cardiovascular risk profile for use in primary care: the framingham heart study. Circulation 117(6), 743–753 (2008). doi:10.1161/CIRCULATIONAHA.107.699579. Epub 2008 Jan 22
ISTAT Resident population by age, sex and marital status as at 1 January 2012 (2013). http://demo.istat.it/pop2011/index.html. Accessed Feb 2013
StatistischesBundesamt: Population, age and gender in federal states (online). URL:https://www.genesis.destatis.de/genesis/online;jsessionid=D8BEC4376595B0176AD0D42966404B3B.tomcat_GO_1_2?operation=previous&levelindex=3&levelid=1361789430099&step=3. Accessed 25 Feb 2013
Population census (2011) INE www.ine.es
Insee, estimations de population (2012) (résultats provisoires arrêtés à fin 2012)
Office for National Statistics, Mid-2010 Population Estimates: England; estimated resident population by single year of age and sex; revised in light of the 2011 census
Osservatorio Epidemiologico Cardiovascolare: Atlante italiano delle malattie cardiovascolari—seconda edizione 2004 Ital. Heart J. (2nd ed) 5(3):1S–101S
Prugger, C., Heuschmann, P.U., Keil, U.: Epidemiologie der Hypertonie in Deutschlandundweltweit. Herz 31, 287–293 (2006)
Banegas, J.R., et al.: Hipertensión arterial y política de salud en España”, MedicinaClinica, 132 (6): 222–229. Banegas JR, Graciani A, de la Cruz-Troca JJ, León-Muñoz LM, Guallar-Castillón P, Coca A, Ruilope LM, Rodríguez-Artalejo F. (2012): “Achievement of Cardiometabolic Goals in Aware Hypertensive Patients in Spain: a Nationwide Population-Based Study. Hypertension 60(4), 898–905 (2012)
Banegas, J.R., Graciani, A., de la Cruz-Troca, J.J., León-Muñoz, L.M., Guallar-Castillón, P., Coca, A., Ruilope, L.M., Rodríguez-Artalejo, F.: Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study. Hypertension 60(4), 898–905 (2012)
Godet-Thobie H., Vernay M. et al. Niveau tensionnel moyen t prévalence de l’hypertension chez les adultes de 18 à 74 ans, ENNS 2006-2007. Bulletin Epidémiologique Hebdomadaire. N°49-50, (2008)
Health Survey for England 2011. Volume 1, chapter 3: Hypertension. The Health and Social care Information Centre, London.
Wagner A., Arveiler D. et al. Etat des lieux sur l’hypertension artérielle en France en 2007: l’étude Mona Lisa. Bulletin Epidémiologique Hebdomadaire. No.49-50, (2008)
HigherHealth Institute. RapportonazionalePassi 2009: rischiocardiovascolare. http://www.epicentro.iss.it/passi/cardiovascolare09.asp. Accessed Feb 2013
Gandjour, A., Lauterbach, K.W.: Wann lohnt es, eine medizinische Überversorgung abzubauen? Das Beispiel der VerschreibungteurerAntihypertonika. MedizinischeKlinik 100, 535–541 (2005)
Hypertension prevalence from Health Survey for England 2011. Volume 1, chapter 3: Hypertension. The Health and Social care Information Centre, London. Diagnosed numbers from NHS Information Centre, Quality and Outcomes Framework (QOF) for April 2011–March 2012, England; 2010–2011 data
Italian Pharmaceutical Agency (AIFA). OSMED report 2011. http://www.agenziafarmaco.gov.it/it/content/rapporti-osmed-luso-dei-farmaci-italia. Accessed May 2013
Laux, G., Szecsenyi, J., Miksch, A., Grün, B., Gutscher, A., Rosemann, T., Kühlein, T.: Antihypertensive medikamentöse Therapie von gesetzlich und privat versicherten Patienten in der Primärversorgung. MedizinischeKlinik 104, 108–113 (2009)
Sicras-Mainar A., Navarro-Artieda R. updated from 2007 data into 2011 values with PCI data from the INE (2009)
MEDIC’AM 2011, http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/donnees-statistiques/medicament/medic-am-2008-2011.php
NICE clinical guideline CG127 Hypertension: costing template: http://guidance.nice.org.uk/CG127/CG34CostingTemplate/xls/English
Conferenza delle Regioni e delle Province Autonome. Tariffa Unica Convenzionale (2011). http://www.regioni.it/download.php?id=254443&field=allegato&module=news
InEK GmbH: Auswertung im Rahmen der Begleitforschung für das Datenjahr 2010 (online). URL: http://www.g-drg.de/cms/content/view/full/3489. Accessed 1 Mar 2013
InEK GmbH: Fallpauschalen-Katalog 2011 [online]. URL: http://www.g-drg.de/cms/content/view/full/3489. Accessed 1 Mar 2013
Ministerio de Sanidad. Servicios Sociales e Igualdad: Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. CMBD. Norma Estatal- NORMA AÑO 2011 AP 27 (2011)
ATIH (Agence Technique de l’Information sur l’Hospitalisation) base des séjours hospitaliers 2011. tousétabliussements. France entière
Tariffs for public hospitals according to official tariffs for 2011. Arrêté du 1 mars 2011
NHS Reference Costs for England: Financial year 2011 to 2012. 8th November 2012, Department of Health, London. https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012. Accessed 12 June 2013
Hense, H.W., Schulte, H., Lowel, H., et al.: Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. Eur. Heart J. 24(10), 937–945 (2003)
Gómez-Marcos, M.A., Martínez-Salgado, C., Martin-Cantera, C., Recio-Rodríguez, J.I., Castaño-Sánchez, Y., Giné-Garriga, M., Rodriguez-Sanchez, E., García-Ortiz, L.: Therapeutic implications of selecting the SCORE (European) versus the D’AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients. BMC Cardiovasc. Disord. 11(9), 17 (2009). doi:10.1186/1471-2261-9-17
Gonzalez, C., Rodilla, E., Costa, J.A., Justicia, J., Pascual, J.M.: Cardiovascular risk by Framingham and SCORE in patients 40–65 years old. Med. Clin. (Barc) 126(14), 527–531 (2006)
Maiques Galan, A., Anton Garcia, F., Franch Taix, M., Albert Ros, X., Aleixandre Marti, E., Collado Gil, A.: Cardiovascular risk of SCORE compared to Framingham. Consequences of the change proposed by the European societies. Med. Clin. (Barc) 123(18), 681–685 (2004)